12:00 AM
 | 
Jan 23, 2012
 |  BC Week In Review  |  Company News  |  Other News

Alnylam, Isis, Tekmira drug delivery news

Alnylam and Isis filed suit in the U.S. District Court for the District of Massachusetts alleging that Tekmira infringed Alnylam's patents covering its siRNA and lipid nanoparticle drug delivery technologies. Alnylam said that by providing lipid nanoparticle-formulated siRNA molecules to Bristol-Myers Squibb Co. (NYSE:BMY, New York, N.Y.) under a 2010 deal, Tekmira infringed Alnylam's U.S. Patent Nos. 7,695,902, 6,858,225,...

Read the full 281 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >